This paper reviews genetic variations mainly related to the onset of adverse events during aromatase inhibitors in early breast cancer. Genetic variability could occur at different steps. The analysis included studies that involved breast cancer patients, treated with an aromatase inhibitor, genotyped for CYP19A1 and/or CYP17A1 and/or CYP27B1 and/or TCLA1, and/or RANK/RANKL/OPG and/or ESR1/ESR2, and assessed for toxicity profile. Twenty-two articles were included for the analysis. Three studies evaluated outcomes and adverse events; 19 studies assessed only side effects. Functional variations may be useful in predicting the onset of toxicities. The identification of polymorphisms at increased risk of toxicity may enable patient management. However, more data are needed to be applied in the individualization of treatment in daily practice.

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients / Sini, V.; Botticelli, A.; Lunardi, G.; Gori, S.; Marchetti, P.. - In: PHARMACOGENOMICS. - ISSN 1462-2416. - 18:8(2017), pp. 821-830-830. [10.2217/pgs-2017-0006]

Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients

Sini V.;Botticelli A.;Marchetti P.
2017

Abstract

This paper reviews genetic variations mainly related to the onset of adverse events during aromatase inhibitors in early breast cancer. Genetic variability could occur at different steps. The analysis included studies that involved breast cancer patients, treated with an aromatase inhibitor, genotyped for CYP19A1 and/or CYP17A1 and/or CYP27B1 and/or TCLA1, and/or RANK/RANKL/OPG and/or ESR1/ESR2, and assessed for toxicity profile. Twenty-two articles were included for the analysis. Three studies evaluated outcomes and adverse events; 19 studies assessed only side effects. Functional variations may be useful in predicting the onset of toxicities. The identification of polymorphisms at increased risk of toxicity may enable patient management. However, more data are needed to be applied in the individualization of treatment in daily practice.
2017
aromatase inhibitors; breast cancer; pharmacogenetics; polymorphism; side effects; Aromatase Inhibitors; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Humans; Pharmacogenetics; Polymorphism, Single Nucleotide
01 Pubblicazione su rivista::01a Articolo in rivista
Pharmacogenetics and aromatase inhibitor induced side effects in breast cancer patients / Sini, V.; Botticelli, A.; Lunardi, G.; Gori, S.; Marchetti, P.. - In: PHARMACOGENOMICS. - ISSN 1462-2416. - 18:8(2017), pp. 821-830-830. [10.2217/pgs-2017-0006]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1330098
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 13
social impact